Osteoporosis in Health and Disease: A Dermatologist's Perspective

Dermatologic Clinics

Volumn 24, Issue 2, 2006, Pages 241-249

  Lamb, Angela ^a   Werth, Victoria ^b,c  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Philadelphia VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; CORTICOSTEROID; ESTROGEN; GESTAGEN; GLUCOCORTICOID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PREDNISONE; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

AGING; ASIA; BLISTER; BLOOD CLOTTING DISORDER; BONE NECROSIS; BREAST CANCER; CORONARY ARTERY DISEASE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE COURSE; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; EUROPE; FLUSHING; FRACTURE; GASTROINTESTINAL IRRITATION; GROWTH RETARDATION; HEREDITY; HUMAN; HYPERPARATHYROIDISM; JAW DISEASE; NAUSEA; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PHYSICAL ACTIVITY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; UNITED STATES; VITAMIN INTAKE; CHEMICALLY INDUCED DISORDER; DERMATOLOGY; PATHOLOGY; SKIN DISEASE;

ADRENAL CORTEX HORMONES; DERMATOLOGY; HUMANS; OSTEOPOROSIS; SKIN DISEASES;

EID: 33745315697     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2006.01.013     Document Type: Review

References (68)

1. Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 1997;7(1):1-6
2. Gallagher J.C. Pathophysiology of osteoporosis. Semin Nephrol 12 2 (1992) 109-115
3. Kanis J.A., Melton III L.J., Christiansen C., et al. The diagnosis of osteoporosis. J Bone Miner Res 9 8 (1994) 1137-1141
4. Leib E.S. Treatment of low bone mass in premenopausal women: when may it be appropriate?. Curr Osteoporos Rep 3 1 (2005) 13-18
5. Templeton K. Secondary osteoporosis. J Am Acad Orthop Surg 13 7 (2005) 475-486
6. Adinoff A.D., and Hollister J.R. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 309 5 (1983) 265-268
7. Michel B.A., Bloch D.A., and Fries J.F. Predictors of fractures in early rheumatoid arthritis. J Rheumatol 18 6 (1991) 804-808
8. Recker R.R., Davies K.M., Hinders S.M., et al. Bone gain in young adult women. JAMA 268 17 (1992) 2403-2408
9. Rosen C.J. Pathophysiology of osteoporosis. Clin Lab Med 20 3 (2000) 455-468
10. Chesnut III C.H. Theoretical overview: bone development, peak bone mass, bone loss, and fracture risk. Am J Med 91 5B (1991) 2S-4S
11. Rubin C.T., Bain S.D., and McLeod K.J. Suppression of the osteogenic response in the aging skeleton. Calcif Tissue Int 50 4 (1992) 306-313
12. Khosla S., Melton III L.J., Atkinson E.J., et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 86 8 (2001) 3555-3561
13. Manolagas S.C., and Jilka R.L. Cytokines, hematopoiesis, osteoclastogenesis, and estrogens. Calcif Tissue Int 50 3 (1992) 199-202
14. Cohen-Solal M., Marie P., and De Vernejoul M.C. [Pathophysiology and genetics of osteoporosis]. Ann Med Interne (Paris) 151 5 (2000) 373-379
15. Schwartz E.N., and Steinberg D. Detection of vertebral fractures. Curr Osteoporos Rep 3 4 (2005) 126-135
16. Kwong L.M. Hip fracture and venous thromboembolism in the elderly. J Surg Orthop Adv 13 3 (2004) 139-148
17. Schwartz H.A. Measurement of bone density: comment on the American College of Rheumatology recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 40 8 (1997) 1551
18. Shaker J.L., and Lukert B.P. Osteoporosis associated with excess glucocorticoids. Endocrinol Metab Clin North Am 34 2 (2005) 341-356 [viii-ix.]
19. Adachi J.D. Corticosteroid-induced osteoporosis. Am J Med Sci 313 1 (1997) 41-49
20. Weinstein R.S., Jilka R.L., Parfitt A.M., et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102 2 (1998) 274-282
21. Dovio A., Perazzolo L., Osella G., et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 89 10 (2004) 4923-4928
22. Zelissen P.M., Croughs R.J., van Rijk P.P., et al. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 120 3 (1994) 207-210
23. Rubin M.R., and Bilezikian J.P. Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 87 9 (2002) 4033-4041
24. Hahn T.J., Halstead L.R., Teitelbaum S.L., et al. Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. J Clin Invest 64 2 (1979) 655-665
25. Hahn T.J., Halstead L.R., and Baran D.T. Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab 52 1 (1981) 111-115
26. Nielsen H.K., Thomsen K., Eriksen E.F., et al. The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects. Bone Miner 4 1 (1988) 105-113
27. Lukert B.P., Kipp D., and Broy S. Management of glucocorticoid-induced osteoporosis-first, do no harm: comment on the American College of Rheumatology recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 40 8 (1997) 1548
28. Suzuki Y., et al. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 32 2 (1983) 151-156
29. Morrison D., Ali N.J., Routledge P.A., et al. Bone turnover during short course prednisolone treatment in patients with chronic obstructive airways disease. Thorax 47 6 (1992) 418-420
30. Goldstein M.F., Fallon Jr. J.J., and Harning R. Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease. Chest 116 6 (1999) 1733-1749
31. Luengo M., Pons F., Martinez de Osaba M.J., et al. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. Thorax 49 11 (1994) 1099-1102
32. Montemurro L., Schiraldi G., Fraioli P., et al. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 49 2 (1991) 71-76
33. Lane N.E., Sanchez S., Modin G.W., et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102 8 (1998) 1627-1633
34. Van Staa T.P., Leufkens H.G., Abenhaim L., et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15 6 (2000) 993-1000
35. Mosekilde L., and Melsen F. A tetracycline-based histomorphometric evaluation of bone resorption and bone turnover in hyperthyroidism and hyperparathyroidism. Acta Med Scand 204 1-2 (1978) 97-102
36. Reid I.R., Schooler B.A., and Stewart A.W. Prevention of glucocorticoid-induced osteoporosis. J Bone Miner Res 5 6 (1990) 619-623
37. Gennari C., and Imbimbo B. Effects of prednisone and deflazacort on vertebral bone mass. Calcif Tissue Int 37 6 (1985) 592-593
38. Reid I.R. Preventing glucocorticoid-induced osteoporosis. Z Rheumatol 59 Suppl 2 (2000) II/97-II/102
39. Cohen S., Levy R.M., Keller M., et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42 11 (1999) 2309-2318
40. Kanis J.A., Johansson H., Oden A., et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19 6 (2004) 893-899
41. van Staa T.P., Leufkens H.G., and Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13 10 (2002) 777-787
42. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44 7 (2001) 1496-1503
43. Task Force on Osteoporosis, and American College of Rheumatology. ACR recommendations target prevention and treatment of glucocorticoid-induced osteoporosis. Am Fam Physician 55 4 (1997) 1450-1453
44. Yosipovitch G., and Hoon T.S. Leok glucocorticoid. Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients. Arch Dermatol 137 4 (2001) 477-481
45. Curtis J.R., Westfall A.O., Allison J.J., et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 52 8 (2005) 2485-2494
46. Amin S., LaValley M.P., Simms R.W., et al. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 42 8 (1999) 1740-1751
47. Adachi J.D., Bensen W.G., Bianchi F., et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 23 6 (1996) 995-1000
48. Saag K.G., Emkey R., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339 5 (1998) 292-299
49. Adachi J.D., Saag K.G., Delmas P.D., et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44 1 (2001) 202-211
50. Simon J.A., Lewiecki E.M., Smith M.E., et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24 11 (2002) 1871-1886
51. Eastell R., Devogelaer J.P., Peel N.F., et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 11 4 (2000) 331-337
52. Reid D.M., Hughes R.A., Laan R.F., et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15 6 (2000) 1006-1013
53. Reginster J.Y., Adami S., Lakatos P., et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2005
54. Reid I.R., Brown J.P., Burckhardt P., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346 9 (2002) 653-661
55. Boutsen Y., Jamart J., Esselinckx W., et al. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tissue Int 61 4 (1997) 266-271
56. Boutsen Y., Jamart J., Esselinckx W., et al. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 16 1 (2001) 104-112
57. Frediani B., Falsetti P., Baldi F., et al. Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound. Bone 33 4 (2003) 575-581
58. Assael L.A. New foundations in understanding osteonecrosis of the jaws. J Oral Maxillofac Surg 62 2 (2004) 125-126
59. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 5 (2004) 527-534
60. Wang J., Goodger N.M., and Pogrel M.A. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61 9 (2003) 1104-1107
61. Vogelvang T.E., van der Mooren M.J., and Mijatovic V. Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications. Treat Endocrinol 3 2 (2004) 105-115
62. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 7 (1999) 637-645
63. Delmas P.D., Bjarnason N.H., Mitlak B.H., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337 23 (1997) 1641-1647
64. Cranney A., Tugwell P., Zytaruk N., et al. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 23 4 (2002) 540-551
65. Adachi J.D., Bensen W.G., Bell M.J., et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 36 2 (1997) 255-259
66. Fudman E.J. Lack of efficacy of calcitonin in preventing glucocorticoid-induced bone loss: comment on the American College of Rheumatology recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 40 8 (1997) 1549
67. Hodsman A.B., Bauer D.C., Dempster D.W., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26 5 (2005) 688-703
68. Body J.J., Gaich G.A., Scheele W.H., et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87 10 (2002) 4528-4535